Author: admin

The extensive report offers a thorough examination of the market potential and market share of NurOwn (MSC-NTF Cells) in the therapeutics landscape for Amyotrophic Lateral Sclerosis across the 7MM spanning the years 2019 to 2032. By delving into this analysis, stakeholders gain valuable insights into the evolving landscape of NurOwn (MSC-NTF Cells), encompassing both clinical and commercial dimensions. Key parameters such as the drug’s Mechanism of Action (MOA), Route of Administration (ROA), dosage, and any special designations are meticulously explored, providing a holistic understanding of its profile.

NurOwn (MSC-NTF Cells) Drug Insights

MSC-NTF cells, also known as NurOwn, represent a groundbreaking approach in regenerative medicine. Derived from the patient’s own bone marrow, these mesenchymal stem cells (MSCs) undergo a specialized culture process to stimulate the secretion of potent neurotrophic factors (NTFs). These factors play a vital role in promoting the growth and survival of neurons, offering a promising avenue for treating neurodegenerative conditions.

By harnessing the innate therapeutic properties of MSCs alongside the enhanced secretion of NTFs, MSC-NTF cells provide a unique combination of benefits. Not only do they possess the immunomodulatory abilities inherent to MSCs, but they also offer heightened support for neuronal health and function.

This innovative approach holds great potential for addressing a wide range of neurological disorders, from Parkinson’s disease to amyotrophic lateral sclerosis (ALS). By leveraging the synergistic effects of MSCs and NTFs, MSC-NTF therapy offers new hope for patients seeking effective treatments that target the underlying mechanisms of neurodegeneration.

As research in this field continues to advance, MSC-NTF cells stand out as a promising avenue for improving the lives of those affected by neurological conditions. With ongoing studies and clinical trials, the potential applications of this technology are continually expanding, paving the way for a brighter future in neuroregenerative medicine.

In December 2021, the FDA granted authorization for additional NurOwn dosing within the Expanded Access Program (EAP). Following this authorization, BrainStorm received a recommendation from the FDA to submit an amendment to the EAP protocol, allowing for additional dosing for eligible participants. Initially, under the original EAP protocol, participants who had successfully completed the Phase III NurOwn trial and met specific criteria were eligible to receive three doses of NurOwn. However, with the amended EAP protocol, these qualifying participants now have the opportunity to receive up to three additional doses. The decision to proceed with these additional doses was informed by data collected from the initial EAP treatments, underscoring the importance of evidence-based decision-making in advancing patient care.

Get a detailed overview of the NurOwn (MSC-NTF Cells) drug and stay ahead of the competition by leveraging key insights and evolving trends in the  Amyotrophic Lateral Sclerosis therapeutic market @

https://www.delveinsight.com/sample-request/nurown-msc-ntf-cells-emerging-drug-insight-and-market-forecast

Key Highlights of the NurOwn (MSC-NTF Cells) Market Report

• The report includes a projected assessment of NurOwn (MSC-NTF Cells) sales for Amyotrophic Lateral Sclerosis up to the year 2032.

• The report offers in-depth coverage of advanced-stage emerging therapies for the treatment of Amyotrophic Lateral Sclerosis.

• The report additionally includes both qualitative and quantitative analyses conducted by analysts, along with Key Opinion Leader (KOL) perspectives on NurOwn (MSC-NTF Cells) for Amyotrophic Lateral Sclerosis.

Why NurOwn (MSC-NTF Cells) Market Report?

• The projected market data for NurOwn (MSC-NTF Cells) in the context of Amyotrophic Lateral Sclerosis will play a crucial role in informing decision-making related to the therapeutic portfolio. It will provide valuable insights into the overall landscape of NurOwn (MSC-NTF Cells), aiding in strategic planning and decision-making processes within the therapeutic domain.

• A comprehensive market forecast for NurOwn (MSC-NTF Cells) will contribute to a better understanding of how the drug competes with other emerging therapies within the therapeutics landscape. This analysis will provide insights into the drug’s positioning, potential market share, and overall impact on the competitive environment in the therapeutic field.

• The report additionally offers future market assessments for the NurOwn (MSC-NTF Cells) market in the field of Amyotrophic Lateral Sclerosis across the 7 Major Markets. It encompasses advanced qualitative analyses such as SWOT analysis, insights from expert analysts, a comprehensive overview of market competitors, and a brief analysis of other emerging therapies within the realm of Amyotrophic Lateral Sclerosis. This multifaceted approach ensures a comprehensive understanding of the NurOwn (MSC-NTF Cells) market landscape, combining both quantitative and qualitative perspectives for a well-rounded assessment.

• Conducting a thorough market forecast for NurOwn (MSC-NTF Cells) will facilitate a detailed analysis of the drug’s clinical trial progress. This examination will encompass a comprehensive assessment of the clinical, regulatory, and commercial aspects, providing valuable insights into the advancements of NurOwn (MSC-NTF Cells). 

Explore key clinical, commercial, and regulatory milestones associated with NurOwn (MSC-NTF Cells) by visiting:

https://www.delveinsight.com/sample-request/nurown-msc-ntf-cells-emerging-drug-insight-and-market-forecast

Table of Contents of the Report

1. Report Introduction

2. NurOwn (MSC-NTF Cells) Overview in Amyotrophic Lateral Sclerosis

3. Competitive Landscape (Key Assessment of the Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies Analysis)

5. NurOwn (MSC-NTF Cells) Market Assessment

6. SWOT Analysis

7. Analysts’ Views

8. Appendix

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

* The final table of contents may be subject to change based on user demand.

Request the Sample PDF to Learn More About the Key Offerings of the NurOwn (MSC-NTF Cells) Market Report:

https://www.delveinsight.com/sample-request/nurown-msc-ntf-cells-emerging-drug-insight-and-market-forecast

Other Related Reports By DelveInsight

Amyotrophic Lateral Sclerosis Pipeline Insight

DelveInsight’s “Amyotrophic Lateral Sclerosis Pipeline Insight” report provides comprehensive insights about 90+ companies and 100+ pipeline drugs in the Amyotrophic Lateral Sclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by routes of administration, and molecule types. Furthermore, it further highlights the inactive pipeline products in this space. Some of the key companies in the Amyotrophic Lateral Sclerosis Therapeutics market include Biogen, Sanofi, Novartis Pharmaceuticals, MolecularPartners, Ionis Pharmaceuticals, Denali Therapeutics Inc., AbbVie, Corcept Therapeutics, Woolsey Pharmaceuticals, Ashvattha Therapeutics Inc., NeuroSense Therapeutics Ltd., Retrotope Inc., Clene Nanomedicine, Apellis Pharmaceuticals Inc, and others.

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: NurOwn (MSC-NTF Cells) for Amyotrophic Lateral Sclerosis: Market Size and Share Analysis and Competitive Landscape by DelveInsight | Key Players – Brainstorm-Cell Therapeutics

The extensive report offers a thorough examination of the market potential and market share of ION363 in the therapeutics landscape for Amyotrophic Lateral Sclerosis across the 7MM spanning the years 2019 to 2032. By delving into this analysis, stakeholders gain valuable insights into the evolving landscape of ION363, encompassing both clinical and commercial dimensions. Key parameters such as the drug’s Mechanism of Action (MOA), Route of Administration (ROA), dosage, and any special designations are meticulously explored, providing a holistic understanding of its profile.

ION363 Drug Insights

ION363, an investigational antisense medication, aims to diminish the production of the Fused in Sarcoma (FUS) protein. Referred to as Jacifusen (although not yet an official USAN name), it pays homage to Jaci Hermstad, the inaugural patient treated with this drug within an expanded access program. This medication is being developed for individuals afflicted with a rare genetic variant of ALS, arising from mutations in the FUS gene.

The presence of mutant FUS instigates motor neuron degeneration through a deleterious gain of function mechanism, resulting in the aggregation of the aberrant protein within motor neurons. Experimental studies in a FUS-ALS mouse model demonstrate that antisense-mediated reduction of mutant FUS protein forestalls the loss of motor neurons. The hypothesis posits that diminishing FUS protein levels could potentially halt or reverse disease progression in FUS-ALS patients by addressing its fundamental cause.

With its focus on the underlying pathology of FUS-ALS, ION363 holds promise in mitigating or impeding disease advancement in affected individuals. Currently, the company is engaged in a Phase III clinical trial assessing the efficacy of this drug in ALS patients harboring fused in sarcoma mutations (FUS-ALS), with anticipated data readouts projected for 2025.

Get a detailed overview of the ION363 drug and stay ahead of the competition by leveraging key insights and evolving trends in the  Amyotrophic Lateral Sclerosis therapeutic market:

https://www.delveinsight.com/sample-request/ion363-emerging-drug-insight-and-market-forecast

Key Highlights of the ION363 Market Report

• The report includes a projected assessment of ION363 sales for Amyotrophic Lateral Sclerosis up to the year 2032.
• The report offers in-depth coverage of advanced-stage emerging therapies for the treatment of Amyotrophic Lateral Sclerosis.
• The report additionally includes both qualitative and quantitative analyses conducted by analysts, along with Key Opinion Leader (KOL) perspectives on ION363 for Amyotrophic Lateral Sclerosis.

Why ION363 Market Report?

• The projected market data for ION363 in the context of Amyotrophic Lateral Sclerosis will play a crucial role in informing decision-making related to the therapeutic portfolio. It will provide valuable insights into the overall landscape of ION363, aiding in strategic planning and decision-making processes within the therapeutic domain.
• A comprehensive market forecast for ION363 will contribute to a better understanding of how the drug competes with other emerging therapies within the therapeutics landscape. This analysis will provide insights into the drug’s positioning, potential market share, and overall impact on the competitive environment in the therapeutic field.
• The report additionally offers future market assessments for the ION363 market in the field of Amyotrophic Lateral Sclerosis across the 7 Major Markets. It encompasses advanced qualitative analyses such as SWOT analysis, insights from expert analysts, a comprehensive overview of market competitors, and a brief analysis of other emerging therapies within the realm of Amyotrophic Lateral Sclerosis. This multifaceted approach ensures a comprehensive understanding of the ION363 market landscape, combining both quantitative and qualitative perspectives for a well-rounded assessment.
• Conducting a thorough market forecast for ION363 will facilitate a detailed analysis of the drug’s clinical trial progress. This examination will encompass a comprehensive assessment of the clinical, regulatory, and commercial aspects, providing valuable insights into the advancements of ION363. 

Explore key clinical, commercial, and regulatory milestones associated with ION363 by visiting:

https://www.delveinsight.com/sample-request/ion363-emerging-drug-insight-and-market-forecast

Table of Contents of the Report

1. Report Introduction

2. ION363 Overview in Amyotrophic Lateral Sclerosis 

3. Competitive Landscape (Key Assessment of the Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies Analysis)

5. ION363 Market Assessment

6. SWOT Analysis

7. Analysts’ Views

8. Appendix

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

* The final table of contents may be subject to change based on user demand.

Request the Sample PDF to Learn More About the Key Offerings of the ION363 Market Report:

https://www.delveinsight.com/sample-request/ion363-emerging-drug-insight-and-market-forecast

Other Related Reports By DelveInsight

Amyotrophic Lateral Sclerosis Pipeline Insight

DelveInsight’s “Amyotrophic Lateral Sclerosis Pipeline Insight” report provides comprehensive insights about 90+ companies and 100+ pipeline drugs in the Amyotrophic Lateral Sclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by routes of administration, and molecule types. Furthermore, it further highlights the inactive pipeline products in this space. Some of the key companies in the Amyotrophic Lateral Sclerosis Therapeutics market include Biogen, Sanofi, Novartis Pharmaceuticals, MolecularPartners, Ionis Pharmaceuticals, Denali Therapeutics Inc., AbbVie, Corcept Therapeutics, Woolsey Pharmaceuticals, Ashvattha Therapeutics Inc., NeuroSense Therapeutics Ltd., Retrotope Inc., Clene Nanomedicine, Apellis Pharmaceuticals Inc, and others.

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: ION363 for Amyotrophic Lateral Sclerosis: Market Size and Share Analysis and Competitive Landscape by DelveInsight | Key Players – Ionis Pharmaceuticals

“DelveInsight Business Research LLP”

The extensive report offers a thorough examination of the market potential and market share of ANX005 in the therapeutics landscape for Huntington’s Disease across the 7MM spanning the years 2019 to 2032. By delving into this analysis, stakeholders gain valuable insights into the evolving landscape of ANX005, encompassing both clinical and commercial dimensions. Key parameters such as the drug’s Mechanism of Action (MOA), Route of Administration (ROA), dosage, and any special designations are meticulously explored, providing a holistic understanding of its profile.

ANX005 Drug Insights

ANX005, a groundbreaking monoclonal antibody under investigation in clinical stages, aims to address the complex spectrum of antibody-mediated autoimmune and complement-mediated neurodegenerative disorders. This innovative therapeutic approach is specifically tailored for intravenous delivery, strategically targeting the inhibition of C1q and the comprehensive classical complement pathway.

Encouragingly, ANX005 demonstrated a favorable safety profile throughout the trial, with consistent findings aligning with interim results previously disclosed. The collective data from ongoing evaluations indicate that ANX005 has been administered and tolerated satisfactorily in a diverse cohort, encompassing over 170 patients across various indications. These results underscore the potential of ANX005 as a promising candidate in the realm of autoimmune and neurodegenerative disease management.

Get a detailed overview of the ANX005 drug and stay ahead of the competition by leveraging key insights and evolving trends in the  Huntington’s Disease therapeutic market @

https://www.delveinsight.com/sample-request/anx005-huntingtons-disease-emerging-drug-insight-and-market-forecast

ANX005 Market Outlook and Key Assessment

Key Highlights of the ANX005 Market Report

• The report includes a projected assessment of ANX005 sales for Huntington’s Disease up to the year 2032.
• The report offers in-depth coverage of advanced-stage emerging therapies for the treatment of Huntington’s Disease.
• The report additionally includes both qualitative and quantitative analyses conducted by analysts, along with Key Opinion Leader (KOL) perspectives on ANX005 for Huntington’s Disease.

Why ANX005 Market Report?

• The projected market data for ANX005 in the context of Huntington’s Disease will play a crucial role in informing decision-making related to the therapeutic portfolio. It will provide valuable insights into the overall landscape of ANX005, aiding in strategic planning and decision-making processes within the therapeutic domain.
• A comprehensive market forecast for ANX005 will contribute to a better understanding of how the drug competes with other emerging therapies within the therapeutics landscape. This analysis will provide insights into the drug’s positioning, potential market share, and overall impact on the competitive environment in the therapeutic field.
• The report additionally offers future market assessments for the ANX005 market in the field of Huntington’s Disease across the 7 Major Markets. It encompasses advanced qualitative analyses such as SWOT analysis, insights from expert analysts, a comprehensive overview of market competitors, and a brief analysis of other emerging therapies within the realm of Huntington’s Disease. This multifaceted approach ensures a comprehensive understanding of the ANX005 market landscape, combining both quantitative and qualitative perspectives for a well-rounded assessment.
• Conducting a thorough market forecast for ANX005 will facilitate a detailed analysis of the drug’s clinical trial progress. This examination will encompass a comprehensive assessment of the clinical, regulatory, and commercial aspects, providing valuable insights into the advancements of ANX005. 

Explore key clinical, commercial, and regulatory milestones associated with ANX005 by visiting:

https://www.delveinsight.com/sample-request/anx005-huntingtons-disease-emerging-drug-insight-and-market-forecast

Table of Contents of the Report

1. Report Introduction

2. ANX005 Overview in Huntington’s Disease

3. Competitive Landscape (Key Assessment of the Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies Analysis)

5. ANX005 Market Assessment

6. SWOT Analysis

7. Analysts’ Views

8. Appendix

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

* The final table of contents may be subject to change based on user demand.

Request the Sample PDF to Learn More About the Key Offerings of the ANX005 Market Report:

https://www.delveinsight.com/sample-request/anx005-huntingtons-disease-emerging-drug-insight-and-market-forecast

Other Related Reports By DelveInsight

Huntington’s Disease Pipeline Insight

DelveInsight’s “Huntington’s Disease Pipeline Insight” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Huntington’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by routes of administration, and molecule types. Furthermore, it further highlights the inactive pipeline products in this space. Some of the key companies in the Huntington’s Disease Therapeutics market include Prilenia Therapeutics, Ionis Pharmaceuticals, Annexon, Vaccinex, Neurocrine Biosciences, EIP Pharma, SAGE Therapeutics, Celon Pharma, PTC Therapeutics, WaVe Life Sciences, Amsterdam Molecular Therapeutics, Novartis, Retrotope, Hope Biosciences, Stealth BioTherapeutics, Luye Pharma Group, Neurimmune Therapeutics, SOLA Biosciences, and others.

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: ANX005 for Huntington’s Disease: Market Size and Share Analysis and Competitive Landscape by DelveInsight | Key Players – Annexon Biosciences

“Delveinsight Business Research LLP”

This evolution is further propelled by ongoing research efforts aimed at identifying novel therapeutic targets and developing innovative interventions to address the complex needs of individuals living with Dravet Syndrome.

DelveInsight’s “Dravet Syndrome Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Dravet Syndrome market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Dravet Syndrome drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Dravet Syndrome treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Dravet Syndrome: An Overview

According to the National Organization for Rare Disorders (NORD), Dravet Syndrome (DS) is a severe form of epilepsy characterized by frequent, prolonged seizures often triggered by high body temperature (hyperthermia), developmental delay, speech impairment, ataxia, hypotonia, sleep disturbances, and other health problems.

Dravet Syndrome Foundation, states that Dravet Syndrome is a rare, catastrophic, lifelong form of epilepsy that begins in the first year of life with frequent and/or prolonged seizures. Three stages usually associated with Dravet Syndrome are febrile, worsening, and stabilization.

At present, there is no organizational or authoritative consensus on the diagnostic principles of Dravet Syndrome. Patient populations involving children are initially misdiagnosed, as the tests used to evaluate epilepsy, MRI, and EEG, appear normal at first instance in babies with Dravet syndrome.

Dravet Syndrome Market Key Facts

• In 2022, total incident cases of Dravet Syndrome in the US have been estimated at around 21,760.
• In France, the total diagnosed cases of Dravet Syndrome have been estimated at around 1,050 cases in 2022, which is estimated to increase by 2032.
• According to the Dravet Syndrome Foundation (2022), a recent US epidemiology study concluded that Dravet Syndrome is twice as common as previously recognized, affecting 1:15,700 infants, 80% of whom have an SCN1A mutation.
• As per the study by Gil-Nagel et al. (2019), the average incidence rate among pediatric and adult patients is 1.1 cases and 0.5 cases per million inhabitants, respectively in Spain.
• In the UK, total treated cases of Dravet Syndrome have been estimated at around 1,000 cases in 2022, which is estimated to increase by 2032.

Dravet Syndrome Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Dravet Syndrome pipeline therapies. It also thoroughly assesses the Dravet Syndrome market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Dravet Syndrome drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Dravet Syndrome Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Dravet Syndrome epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Dravet Syndrome epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Dravet Syndrome Epidemiology, Segmented as –

• Total Incident Cases of Dravet Syndrome in the 7MM [2019–2032]
• Total Diagnosed Cases of Dravet Syndrome in the 7MM
• Mutation-Specific Incident Cases of Dravet Syndrome in the 7MM [2019–2032]
• Age-specific Incident Cases of Dravet Syndrome in the 7MM [2019–2032]
• Gender-specific Incident Cases of Dravet Syndrome in the 7MM [2019–2032]
• Total Treated Cases of Dravet Syndrome in the 7MM [2019–2032]

Dravet Syndrome Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Dravet Syndrome market or expected to be launched during the study period. The analysis covers the Dravet Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares Dravet Syndrome drugs based on their sale and market share.

The report also covers the Dravet Syndrome pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Dravet Syndrome companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Dravet Syndrome Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/dravet-syndrome-market

Dravet Syndrome Therapeutics Analysis

The available therapeutics treatment options in the Dravet Syndrome landscape aim to provide a cure to the patients suffering from this indication; however, there are several challenges that are yet to be tackled. Pharmaceutical companies have shifted their focus toward the current needs faced by Dravet Syndrome. There are some novel and strong emerging therapies that can change the treatment landscape of Dravet syndrome. Active Support from both organizations and pharma companies, which are rigorously working in order to find a better way to help the family with Dravet Syndrome. Efforts are made to increase awareness among people in collaboration with pharma companies. Currently, Takeda is leading the therapeutics market with its Dravet Syndrome drug candidates in the most advanced stage of clinical development.

Dravet Syndrome Companies Actively Working in the Therapeutics Market Include

• Takeda
• Epygenix Therapeutics
• Stoke Therapeutics
• Longboard Pharmaceuticals
• Encoded Therapeutics
• Eisai
• Virpax Pharmaceuticals
• Biocodex
• GW Pharmaceuticals
• Zogenix
• Ovid Therapeutics
• PTC Therapeutics

And Many Others

Emerging and Marketed Dravet Syndrome Therapies Covered in the Report Include:

• Soticlestat: Takeda
• EPX-100: Epygenix Therapeutics
• STK-001: Stoke Therapeutics
• LP352: Longboard Pharmaceuticals

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

https://www.delveinsight.com/sample-request/dravet-syndrome-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Dravet Syndrome Competitive Intelligence Analysis

4. Dravet Syndrome Market Overview at a Glance

5. Dravet Syndrome Disease Background and Overview

6. Dravet Syndrome Patient Journey

7. Dravet Syndrome Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Dravet Syndrome Treatment Algorithm, Current Treatment, and Medical Practices

9. Dravet Syndrome Unmet Needs

10. Key Endpoints of Dravet Syndrome Treatment

11. Dravet Syndrome Marketed Therapies

12. Dravet Syndrome Emerging Drugs and Latest Therapeutic Advances

13. Dravet Syndrome Seven Major Market Analysis

14. Attribute Analysis

15. Dravet Syndrome Market Outlook (In US, EU5, and Japan)

16. Dravet Syndrome Companies Active in the Market

17. Dravet Syndrome Access and Reimbursement Overview

18. KOL Views on the Dravet Syndrome Market

19. Dravet Syndrome Market Drivers

20. Dravet Syndrome Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/dravet-syndrome-market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Ductal Carcinoma in Situ Market

“Ductal Carcinoma in Situ Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Ductal Carcinoma in Situ market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Ductal Carcinoma in Situ market.a

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/oncology

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dravet Syndrome Market Set to Grow at an Impressive Growth Rate Through 2032 – Asserts Delveinsight | Takeda, Epygenix, Eisai, Biocodex, Zogenix, Virpax, Ovid Therapeutics, Encoded Therapeutics

“Delveinsight Business Research LLP”

Concurrently, advancements in diagnostic tools and biomarker identification are facilitating earlier detection and intervention, a crucial factor in improving patient outcomes.

DelveInsight’s “Sjogren’s Syndrome Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Sjogren’s Syndrome market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Sjogren’s Syndrome drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Sjogren’s Syndrome treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Sjogren’s Syndrome: An Overview

Sjogren’s Syndrome (SS) is an autoimmune disorder caused by the lymphocytic infiltration of exocrine glands resulting in glandular dysfunction, particularly of the salivary and lacrimal glands. It can be classified into two types, i.e., Primary Sjogren’s Syndrome, and Secondary Sjogren’s Syndrome. Primary Sjogren’s Syndrome (pSS) occurs in the absence of other autoimmune diseases and is characterized by keratoconjunctiva sicca (dry eyes) and xerostomia (dry mouth), collectively called the sicca syndrome. In contrast, Secondary Sjogren’s Syndrome presents, along with other autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

Currently, the pathogenesis of the diseases is not fully understood and is currently thought to be the result of a combination of factors such as genetic defects, immune mechanisms, and virus infections. Increased activation of B cells followed by immune complex formation and autoantibody production, in particular, anti-Ro/SS-A and anti-La/SS-B are thought to play important roles.

Traditional biomarkers for primary SS include serological, molecular, and histological biomarkers that have been primarily used to diagnose the disease and for patients’ prognostic stratification, including the plethora of autoantibodies, salivary glands, histologic lesions, and several laboratory abnormalities.

There is still no single clinical, laboratory, pathological, or radiological feature that could serve as a gold standard for the diagnosis and/or classification of this syndrome. Labial salivary gland biopsy with a subsequent histopathological evaluation is currently in use.

Sjogren’s Syndrome Market Key Facts

• In 2022, the total diagnosed prevalent cases of Sjögren’s Syndrome were approximately 3,275,500 cases in the 7MM.
• In 2022, the total gender-specific cases of Sjögren’s Syndrome were approximately 175,200 and 1,577,600 cases of males and females, respectively in the United States.
• In 2022, the total number of treated cases of Sjögren’s Syndrome in the 7MM was approximately 3 million cases.
• In 2022, the total severity-specific cases of Sjögren’s Syndrome in the UK were approximately 348,800 and 61,500 cases of mild and moderate to severe severity, respectively, which are expected to grow during the study period, i.e., 2019-2032.

Sjogren’s Syndrome Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Sjogren’s Syndrome pipeline therapies. It also thoroughly assesses the Sjogren’s Syndrome market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Sjogren’s Syndrome drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Sjogren’s Syndrome Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Sjogren’s Syndrome epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Sjogren’s Syndrome epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Sjogren’s Syndrome Epidemiology, Segmented as –

• Total Type-specific Cases of Sjögren’s Syndrome in the 7MM [2019–2032]
• Total Diagnosed Prevalent Cases of Sjögren’s Syndrom in the 7MM [2019–2032]
• Total Treated Cases of Sjögren’s Syndrome in the 7MM [2019–2032]
• Total Gender-specific Cases of Sjögren’s Syndrome in the 7MM [2019–2032]
• Total Severity-specific Cases of Sjögren’s Syndrome in the 7MM [2019–2032]
• Total Antibody-specific Cases of Sjogren’s Syndrome in the 7MM [2019–2032]

Sjogren’s Syndrome Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Sjogren’s Syndrome market or expected to be launched during the study period. The analysis covers the Sjogren’s Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Sjogren’s Syndrome drugs based on their sale and market share.

The report also covers the Sjogren’s Syndrome pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Sjogren’s Syndrome companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Sjogren’s Syndrome Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/sjogrens-syndrome-market-size

Sjogren’s Syndrome Therapeutics Analysis

Currently, there is no cure for Sjogren’s syndrome. The treatment goals remain symptom palliation, prevention of complications, and, for rheumatologists, proper selection of patients for immunosuppressive therapy. Prevention of alcohol and smoking and maintenance of oral hygiene are the preventive methods. Sjogren’s syndrome might not be the best-known autoimmune disease, but the potential market is large enough for the investments. In the last few years, a great effort has been made by the rheumatologic scientific community for this autoimmune condition.

At present, the therapeutic market size of Sjogren’s syndrome in the US is mainly accounted for by local therapies, systemic therapy, and biological therapies. The local therapies mainly include pilocarpine, cevimeline, topical fluoride, topical cyclosporine, autologous serum eye drops, and others. Systemic therapy mainly uses corticosteroids, hydroxychloroquine, and immunosuppressants. Methotrexate (MTX), Cyclosporine A, Azathioprine, Leflunomide, and Mycophenolic acid are also commonly used DMARDs. Biological therapy with Rituximab is in extensive use in the US market. Along with this, TNF-alpha inhibitors, BAFF, and others are in development.

Several major pharma and biotech companies are developing therapies for Sjogren’s syndrome. Currently, Novartis is leading the therapeutics market with its Sjogren’s syndrome drug candidates in the most advanced stage of clinical development.

Sjogren’s Syndrome Companies Actively Working in the Therapeutics Market Include

ADVANZ Pharma, Daiichi Sankyo, Resolve Therapeutics, GlaxoSmithKline, VIELABIO, RemeGen, Bristol Myers Squibb, TearSolutions, Pfizer Inc., AstraZeneca plc, Novartis AG, Sanofi S.A., Roche Holding AG, Johnson & Johnson, AbbVie Inc., Eli Lilly and Company, Biogen Inc., Amgen Inc., Celgene Corporation, Genentech, Inc, Boehringer Ingelheim International GmbH, Takeda Pharmaceutical Company Limited, Gilead Sciences, Inc., Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Bayer AG, and many others.

Emerging and Marketed Sjogren’s Syndrome Therapies Covered in the Report Include:

• VAY736: Novartis
• VIB4920: Horizon Therapeutics

And Many More

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/sjogrens-syndrome-market-size

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Sjogren’s Syndrome Competitive Intelligence Analysis

4. Sjogren’s Syndrome Market Overview at a Glance

5. Sjogren’s Syndrome Disease Background and Overview

6. Sjogren’s Syndrome Patient Journey

7. Sjogren’s Syndrome Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Sjogren’s Syndrome Treatment Algorithm, Current Treatment, and Medical Practices

9. Sjogren’s Syndrome Unmet Needs

10. Key Endpoints of Sjogren’s Syndrome Treatment

11. Sjogren’s Syndrome Marketed Therapies

12. Sjogren’s Syndrome Emerging Drugs and Latest Therapeutic Advances

13. Sjogren’s Syndrome Seven Major Market Analysis

14. Attribute Analysis

15. Sjogren’s Syndrome Market Outlook (In US, EU5, and Japan)

16. Sjogren’s Syndrome Companies Active in the Market

17. Sjogren’s Syndrome Access and Reimbursement Overview

18. KOL Views on the Sjogren’s Syndrome Market

19. Sjogren’s Syndrome Market Drivers

20. Sjogren’s Syndrome Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/sjogrens-syndrome-market-size

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Bronchopulmonary Dysplasia Market

“Bronchopulmonary Dysplasia Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Bronchopulmonary Dysplasia market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Bronchopulmonary Dysplasia market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/oncology

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Sjogren’s Syndrome Market Poised for Phenomenal Expansion During the Forecast Period (2023-32) – DelveInsight | Gilead, Daiichi Sankyo, Bayer, Vielabio, Remegen, Pfizer, Novartis, Genentech

DelveInsight’s “Desmoid Tumors Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Desmoid Tumors market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Desmoid Tumors drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Desmoid Tumors treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Desmoid Tumors: An Overview

Desmoid Tumors (DT) are noncancerous growths that develop in connective tissue. They are also called aggressive fibromatosis as they have similarities with a malignant (cancerous) tumor called fibrosarcoma. However, it is considered benign because it does not metastasize (spread) to other parts of the body. The myofibroblast is the cell responsible for the desmoid tumor. A desmoid tumor can invade surrounding tissues and be difficult to control. They can develop at any body site. Superficial desmoids tend to be less aggressive than deep desmoids (abdominal, extra-abdominal, mesenteric). These tumors look like dense scar tissue. They adhere to surrounding structures and organs and are often difficult to remove.

Desmoid tumors may present sporadically or as a manifestation of hereditary familial adenomatous polyposis (FAP). In most patients, desmoid tumors occur sporadically, meaning that it is not caused by predisposing genetic disease. People who develop desmoid tumors sporadically have no other APC gene-associated health problems. Repeated irritation or trauma to a certain body area, including surgical trauma, may increase the risk of developing desmoid tumor. Estrogen may also play a role in its development.

According to National Organization for Rare Disorders (NORD) data desmoid tumors constitute 0.03% of all tumors. The estimated incidence in the general population is 2-4 per million people per year. Desmoid tumors are observed to be more common in persons aged 10-40 years but can occur in other age groups. Desmoid tumors can commonly occur in women after childbirth. The female: male gender ratio is 2:1. In children, the gender incidence is the same.

Some desmoid tumors are slow-growing and don’t require immediate treatment. Others that grow quickly are treated with surgery, radiation therapy, chemotherapy including anticancer drugs, cryoablation or through combinatorial therapy. Anti-inflammatory drugs may cause the tumor to slowly shrink. Chemotherapy agents used to inhibit growth include Doxorubicin (Adriamycin, Rubex), Dacarabazine (DTIC-Dome), and Carboplatin (Paraplatin). Gleevec and Sorafenib are the two kinase inhibitors that are useful in treating desmoid tumors.

Desmoid Tumors Market Key Facts

• The total prevalent cases of Desmoid Tumors in the US comprised of around 14,000 cases in 2022 and are projected to increase by 2032 with a mild CAGR. 
• As per the DelveInsight estimates, in the 7MM, the highest number of prevalent cases of Desmoid Tumors were observed in the US.
• As per the DelveInsight estimates, around 65% of the diagnosed cases either remain stable or are under active surveillance for spontaneous regression. In 2022, approximately 9,000 cases in the US either remain stable or are under active surveillance for spontaneous regression.
• According to Orphanet somatic mutations in the CTNNB1 gene (3q21) encoding beta-catenin have been found in about 85 % of sporadic cases. In cases with FAP, desmoid tumors have been associated with mutations in the tumor suppressor gene APC (5q21-q22) encoding the adenomatous polyposis coli protein. Most cases are sporadic. Familial cases (5-10 %) are associated with FAP.

Desmoid Tumors Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Desmoid Tumors pipeline therapies. It also thoroughly assesses the Desmoid Tumors market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Desmoid Tumors drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Desmoid Tumors Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Desmoid Tumors epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Desmoid Tumors epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Desmoid Tumors Epidemiology, Segmented as –

• Total Incident Cases of Desmoid Tumor in the 7MM (2019 to 2032)
• Type-specific (Sporadic, Familial) Incident Cases of Desmoid Tumor in the 7MM (2019 to 2032)
• Gender-specific Incident Cases of Desmoid Tumor in the 7MM (2019 to 2032)
• Age-specific Incident Cases of Desmoid Tumor in the 7MM (2019 to 2032)
• Site-specific Incident Cases of Desmoid Tumor in the 7MM (2019 to 2032)
• Treatable Cases of Desmoid Tumor in the 7MM (2019 to 2032)

Desmoid Tumors Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Desmoid Tumors market or expected to be launched during the study period. The analysis covers the Desmoid Tumors market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Desmoid Tumors drugs based on their sale and market share.

The report also covers the Desmoid Tumors pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Desmoid Tumors companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Desmoid Tumors Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/desmoid-tumors-market

Desmoid Tumors Therapeutics Analysis

Several key companies are developing therapies for Desmoid Tumors. Currently, SpringWorks Therapeutics is leading the therapeutics market with its Desmoid Tumors drug candidates in the most advanced stage of clinical development.

Desmoid Tumors Companies Actively Working in the Therapeutics Market Include

• SpringWorks Therapeutics
• Ayala Therapeutics
• Iterion Therapeutics
• Pfizer
• Novartis
• Ayala Pharmaceuticals, Inc,
• Recursion Pharmaceuticals Inc.
• Iterion Therapeutics
• 180 Life Sciences
• AFT Pharma
• Timber Pharmaceuticals
• MedPact
• Intas Pharmaceutical
• Jina pharmaceuticals

And Many Other

Emerging and Marketed Desmoid Tumors Therapies Covered in the Report Include:

• LYNPARZA (olaparib): AstraZeneca and MSD
• Nirogacestat: SpringWorks Therapeutics
• AL102: Ayala Therapeutics
• Tegavivint: Iterion Therapeutics

And Many More

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/desmoid-tumors-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Desmoid Tumors Competitive Intelligence Analysis

4. Desmoid Tumors Market Overview at a Glance

5. Desmoid Tumors Disease Background and Overview

6. Desmoid Tumors Patient Journey

7. Desmoid Tumors Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Desmoid Tumors Treatment Algorithm, Current Treatment, and Medical Practices

9. Desmoid Tumors Unmet Needs

10. Key Endpoints of Desmoid Tumors Treatment

11. Desmoid Tumors Marketed Therapies

12. Desmoid Tumors Emerging Drugs and Latest Therapeutic Advances

13. Desmoid Tumors Seven Major Market Analysis

14. Attribute Analysis

15. Desmoid Tumors Market Outlook (In US, EU5, and Japan)

16. Desmoid Tumors Companies Active in the Market

17. Desmoid Tumors Access and Reimbursement Overview

18. KOL Views on the Desmoid Tumors Market

19. Desmoid Tumors Market Drivers

20. Desmoid Tumors Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/desmoid-tumors-market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Congenital Adrenal Hyperplasia Market

“Congenital Adrenal Hyperplasia Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Congenital Adrenal Hyperplasia market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Congenital Adrenal Hyperplasia market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Desmoid Tumors Market Forecasts by DelveInsight Signal Groundbreaking Growth by 2032 | SpringWorks Therapeutics, Ayala, Pfizer, Novartis, Recursion Pharma, Iterion Therapeutics, AFT Pharma, MedPact